Total Hip Arthroplasty Outcomes Can't Get Worse with Psoriasis

Neither psoriatic arthritis (PsA) nor cutaneous psoriasis (PsC) are considered risk factors for patients undergoing total hip arthroplasty (THA).

Neither psoriatic arthritis (PsA) nor cutaneous psoriasis (PsC) are considered risk factors for patients undergoing total hip arthroplasty (THA).

Lisa A. Mandl, MD, MPH, Hospital for Special Surgery in New York City, led a team of researchers that compared THA outcomes for 63 patients with PsA or PsC with outcomes for 153 patients suffering from osteoarthritis (OA).

Their findings were published in the latest issue of Arthritis & Rheumatology.

The researchers discovered patients with PsA and PsC had higher body mass index and more comorbidities than those with OA. More than half (54%) of PsA patients were treated with biologics or nonbiologic disease-modifying antirheumatic drugs, compared to only 8% of patients with PsC.

In regression analyses, PsA and PsC were not risk factors for worse THA outcomes — all three groups had high satisfaction with outcome.

According to the authors, “This is important information to convey to patients with either PsA or PsC who are contemplating surgical intervention with THA.”